Osteomodulin is a Potential Genetic Target for Hypertrophic Cardiomyopathy

Area of Science:

• Cardiovascular Genetics
• Molecular Cardiology

Background:

• Hypertrophic cardiomyopathy (HCM) is a prevalent genetic heart disease characterized by cardiomyocyte hypertrophy, microvascular issues, and excessive matrix accumulation.
• Understanding the genetic underpinnings of HCM is crucial for developing effective diagnostic and therapeutic strategies.

Purpose of the Study:

• To identify genes involved in HCM pathogenesis using weighted gene co-expression network analysis (WGCNA).
• To construct a miRNA-mRNA network to pinpoint potential hub genes.
• To evaluate the diagnostic capacity and cellular expression of identified hub genes in HCM.

Main Methods:

• Weighted Gene Co-expression Network Analysis (WGCNA) to identify disease-correlated gene modules.
• miRNA-mRNA network construction to predict hub genes.
• Gene Set Enrichment Analysis (GSEA) for functional annotation.
• Receiver Operating Characteristic (ROC) curve analysis for diagnostic evaluation.
• Single-cell RNA sequencing (sc-RNA seq) to determine cell-type specific expression.

Main Results:

• The 'red module' from WGCNA showed the strongest correlation with HCM.
• Osteomodulin (OMD) was identified as a key hub gene through miRNA-mRNA network analysis.
• GSEA indicated OMD's involvement in extracellular matrix synthesis and immune system modulation.
• ROC analysis demonstrated OMD's ability to distinguish HCM from controls (AUC > 0.7).
• sc-RNA seq revealed OMD expression predominantly in late-stage cardiac fibroblasts.

Conclusions:

• Osteomodulin (OMD) plays a significant role in the pathogenesis of hypertrophic cardiomyopathy, potentially through its influence on cardiac fibroblasts and extracellular matrix.
• OMD emerges as a promising biomarker for HCM diagnosis and a potential therapeutic target for future interventions.